Know Cancer

forgot password

A Phase 2 Study of IPI-926 in Patients With Myelofibrosis

Phase 2
18 Years
90 Years
Not Enrolling
Primary Myelofibrosis, Fibrosis, Bone Marrow

Thank you

Trial Information

A Phase 2 Study of IPI-926 in Patients With Myelofibrosis

Inclusion Criteria:

- ≥18 years of age at the time of signing the ICF.

- Voluntarily sign an ICF.

- Pathologically confirmed PMF or post ET/PV MF as per the WHO diagnostic criteria
(note that it must include at least Grade 1 marrow fibrosis, see Appendix 3) with
intermediate-1, intermediate -2, or high risk disease according to the IWG prognostic
scoring system (see Appendix 4). If patients have low risk disease, then they must
have symptomatic splenomegaly that is ≥ 10 cm below left costal margin by physical

- ECOG performance of 0-2.

- Life expectancy of at least 3 months.

- Recovery to Grade 1 or baseline of any toxicities due to prior systemic treatments,
excluding alopecia.

- If a woman, be of non-child bearing potential or, for women of child-bearing
potential (WCBP) (defined as a sexually mature woman who has not undergone surgical
sterilization or who has not been naturally post-menopausal for at least 24
consecutive months for women ≤55 years; for women >55 years 12 consecutive months),
must have a negative serum or urine pregnancy test result within 2 weeks of first
dose of study drug.

- All WCBP and all sexually active male patients must agree to use adequate methods of
birth control throughout the study. Adequate methods of contraception include use of
oral contraceptives with an additional barrier method, double barrier methods
(diaphragm with spermicidal gel or condoms with contraceptive foam), Depo-Provera,
partner vasectomy, and total abstinence.

- Ability to adhere to the study visit schedule and all protocol requirements.

Exclusion Criteria:

- Prior treatment with any inhibitor of the hedgehog pathway (e.g. GDC-0449).

- Received any treatment for myelofibrosis within 2 weeks of study entry.

- Other invasive malignancies diagnosed within the last 3 years, except non-melanoma
skin cancer and localized cured prostate and cervical cancer.

- Inadequate hepatic function defined by:

- Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) >2.5 x upper
limit of normal (ULN).

- Direct bilirubin >1.5 x ULN.

- Cirrhotic liver disease, ongoing alcohol abuse, or known chronic active or acute

- Inadequate renal function defined by serum creatinine >2 x ULN.

- History of stroke, unstable angina, myocardial infarction, or ventricular arrhythmia
requiring medication or mechanical control within the last 6 months.

- Presence of active infection or systemic use of antibiotics within 72 hours of

- Significant co-morbid condition or disease, which in the judgment of the
Investigator, would place the patient at undue risk or interfere with the study.

- Known human immunodeficiency virus (HIV) positivity.

- Known hypersensitivity to IPI-926, or any of the excipients in IPI-926 capsules.

- Pregnant or lactating women.

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To determine the overall response rate of IPI-926, defined as clinical improvement (CI); partial remission (PR); and complete remission (CR), according to the International working group (IWG) criteria in patients with Myelofibrosis

Outcome Time Frame:

At least 2 months

Safety Issue:


Principal Investigator

Srdan Verstovsek, M.D.; Ph.D

Investigator Role:

Principal Investigator

Investigator Affiliation:

M.D. Anderson Cancer Center


United States: Food and Drug Administration

Study ID:




Start Date:

October 2011

Completion Date:

August 2012

Related Keywords:

  • Primary Myelofibrosis
  • Fibrosis, Bone Marrow
  • IPI-926
  • 926
  • Myelofibrosis
  • Hedgehog
  • Infinity Pharmaceuticals
  • Post Essential thrombocythemia
  • Post Polycythemia vera
  • Primary Myelofibrosis
  • Fibrosis



The University of Texas MD Anderson Cancer Center Houston, Texas  77030-4009
Arizona Mayo Clinic Scottsdale, Arizona  85260
Stanford University School of Medicine, Division of Hematology Palo Alto, California  94025